MariTide Maridebart Cafraglutide

📄 7 PubMed citations

Amgen's once-monthly peptide-antibody conjugate that switches the GLP-1 receptor ON and the GIP receptor OFF — and the real story behind the viral 'opposite mechanisms' claim.

🔬 Most coverage parrots the viral line that tirzepatide and MariTide drive weight loss through 'opposite GIPR mechanisms in different brain circuits.' We read the trials and the mechanism reviews: the paradox is real, but that clean explanation isn't — in humans, GIPR agonism or antagonism ALONE shows no clear appetite effect. Here's what the Phase 2 data (NEJM 2025) actually shows.

16.2%

Peak mean weight loss at 52 weeks (Phase 2)

592

Participants in the Phase 2 trial

4 wks

Dosing interval — roughly once a month

Mechanism of Action

How It Works

🧬

GLP-1 Receptor Agonism

Two GLP-1 analog peptides are conjugated to the antibody and activate the GLP-1 receptor — curbing appetite and slowing gastric emptying, the same axis semaglutide and tirzepatide work through.

🚫

GIP Receptor Antagonism

The IgG antibody backbone BLOCKS the GIP receptor instead of activating it. In preclinical and Phase 1 work this GIPR blockade added to GLP-1-driven weight loss.

⏳

Antibody = Weeks-Long Half-Life

Anchoring the GLP-1 peptides to a monoclonal antibody extends their half-life from minutes to weeks, enabling once-monthly — and in some trial arms once-every-8-weeks — subcutaneous dosing.

❓

The GIPR Paradox

Tirzepatide ACTIVATES GIPR; MariTide BLOCKS it — yet both aid weight loss. Reviews note neither GIPR agonism nor antagonism alone shows a clear appetite effect in humans; each may work mainly by amplifying GLP-1 signaling. The mechanism is genuinely unresolved.

Data

What the Data Shows

MariTide — obesity, highest dose

52 weeks, Phase 2

−16.2%

MariTide — obesity, lower doses

52 weeks, Phase 2

−12.3%

MariTide — obesity + type 2 diabetes

52 weeks, top dose

−12.3%

Placebo — obesity cohort

52 weeks

−2.5%

Bottom Line

Key Takeaways

✅ What We Know

MariTide (maridebart cafraglutide, formerly AMG 133) is Amgen's long-acting peptide-antibody conjugate: two GLP-1 receptor agonist peptides attached to a GIP-receptor-blocking antibody.
In a 592-participant Phase 2 trial, once-monthly MariTide produced mean weight loss of −12.3% to −16.2% at 52 weeks in people with obesity, versus −2.5% on placebo.
In participants with obesity AND type 2 diabetes, weight loss ranged −8.4% to −12.3%, versus −1.7% on placebo.
The antibody backbone stretches the drug's half-life to weeks, enabling once-monthly (and in some arms once-every-8-weeks) subcutaneous dosing.
Gastrointestinal side effects (nausea, vomiting) were common but less frequent when the dose was started low and escalated gradually.
MariTide is in Phase 3 trials — it is NOT approved and NOT available for sale.

⚠️ What We Don't Know

Why GIPR ANTAGONISM (MariTide) and GIPR AGONISM (tirzepatide) both aid weight loss is unresolved — reviewers note neither action alone produces a clear appetite effect in humans.
The viral 'different brain circuits' explanation is a hypothesis, not an established finding — head-to-head mechanistic data in humans are lacking.
Long-term (multi-year) efficacy, safety, and durability of weight loss beyond the trial windows are not yet known.
MariTide has not been tested head-to-head against tirzepatide or retatrutide for total weight loss.
Effects on cardiovascular outcomes, muscle preservation, and weight regain after stopping remain under investigation.

FAQ

Frequently Asked Questions

What is MariTide (maridebart cafraglutide)?

MariTide is Amgen's investigational obesity drug — a peptide-antibody conjugate that activates the GLP-1 receptor while blocking the GIP receptor, given by subcutaneous injection roughly once a month. Formerly called AMG 133, it is in Phase 3 trials and not yet approved.

How much weight did people lose on MariTide?

In a Phase 2 trial of 592 people, those with obesity lost a mean of 12.3% to 16.2% of body weight at 52 weeks depending on dose, versus 2.5% on placebo. People with obesity and type 2 diabetes lost 8.4% to 12.3%, versus 1.7% on placebo.

How is MariTide different from Ozempic or Mounjaro?

Two ways. Dosing: MariTide's antibody backbone gives it a weeks-long half-life, allowing once-monthly injections instead of weekly. Mechanism: it BLOCKS the GIP receptor, whereas tirzepatide (Mounjaro/Zepbound) ACTIVATES it, while both also engage the GLP-1 receptor.

How can blocking GIPR and activating GIPR both cause weight loss?

This is a genuine open paradox. Current reviews suggest that in humans, neither GIPR agonism nor GIPR antagonism alone drives appetite loss — both approaches may work mainly by amplifying GLP-1 signaling. The 'different brain circuits' explanation circulating online is an unproven hypothesis, not settled science.

Is MariTide available to buy?

No. MariTide is an investigational Amgen drug in Phase 3 clinical trials — not approved or sold anywhere, and not available from research-chemical vendors. Be skeptical of any site claiming to sell it.